1. Home
  2. COCP vs GNLN Comparison

COCP vs GNLN Comparison

Compare COCP & GNLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COCP
  • GNLN
  • Stock Information
  • Founded
  • COCP 2006
  • GNLN 2005
  • Country
  • COCP United States
  • GNLN United States
  • Employees
  • COCP N/A
  • GNLN N/A
  • Industry
  • COCP Biotechnology: Pharmaceutical Preparations
  • GNLN Durable Goods
  • Sector
  • COCP Health Care
  • GNLN Consumer Discretionary
  • Exchange
  • COCP Nasdaq
  • GNLN Nasdaq
  • Market Cap
  • COCP 15.4M
  • GNLN 12.9M
  • IPO Year
  • COCP N/A
  • GNLN 2019
  • Fundamental
  • Price
  • COCP $1.22
  • GNLN $4.04
  • Analyst Decision
  • COCP Strong Buy
  • GNLN
  • Analyst Count
  • COCP 1
  • GNLN 0
  • Target Price
  • COCP $6.00
  • GNLN N/A
  • AVG Volume (30 Days)
  • COCP 4.6M
  • GNLN 136.5K
  • Earning Date
  • COCP 11-12-2025
  • GNLN 11-14-2025
  • Dividend Yield
  • COCP N/A
  • GNLN N/A
  • EPS Growth
  • COCP N/A
  • GNLN N/A
  • EPS
  • COCP N/A
  • GNLN N/A
  • Revenue
  • COCP N/A
  • GNLN $7,954,000.00
  • Revenue This Year
  • COCP N/A
  • GNLN $1,541.21
  • Revenue Next Year
  • COCP N/A
  • GNLN N/A
  • P/E Ratio
  • COCP N/A
  • GNLN N/A
  • Revenue Growth
  • COCP N/A
  • GNLN N/A
  • 52 Week Low
  • COCP $1.12
  • GNLN $2.84
  • 52 Week High
  • COCP $3.26
  • GNLN $3,975.00
  • Technical
  • Relative Strength Index (RSI)
  • COCP 37.81
  • GNLN 58.84
  • Support Level
  • COCP $1.17
  • GNLN $3.35
  • Resistance Level
  • COCP $1.31
  • GNLN $4.45
  • Average True Range (ATR)
  • COCP 0.09
  • GNLN 0.30
  • MACD
  • COCP -0.00
  • GNLN 0.08
  • Stochastic Oscillator
  • COCP 20.00
  • GNLN 62.73

About COCP Cocrystal Pharma Inc.

Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).

About GNLN Greenlane Holdings Inc.

Greenlane Holdings Inc is a platform for the development and distribution of premium cannabis accessories, vape devices, and lifestyle products. It provides a wide array of consumer ancillary products and industrial ancillary products to thousands of cannabis producers, processors, brands, and retailers (Cannabis Operators). In addition, it serves specialty retailers, smoke shops, head shops, convenience stores, and consumers directly through its proprietary web stores and large online marketplaces such as Amazon. Its geographical segment includes the United States, Canada, and Europe. It derives a majority of revenue from the United States.

Share on Social Networks: